SYNB 021225
Alternative Names: SYNB-021225Latest Information Update: 04 Jul 2025
At a glance
- Originator Syneron Bio
- Class Antineoplastics; Peptides
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 25 Apr 2025 Preclinical trials in Cancer in China (PO) prior to April 2025
- 25 Apr 2025 Pharmacodynamics data from a preclinical studies in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Syneron Bio plans a clinical trial for Cancer